Gelonghui, March 14, 丨 Hanson Pharmaceutical (03692.HK) announced that on March 14, 2024, Hanson (Shanghai) Health Technology Co., Ltd. (licensee), a wholly-owned subsidiary of the company, signed a license agreement with Promise Biotechnology (Zhuhai) Co., Ltd.
According to the license agreement, the licensee obtained an exclusive license from Pumis to develop, produce and commercialize HS-20117 (introduction project name PM1080) for bispecific antibody conjugate products (ADC products) worldwide, and has the right to further sub-license. The licensee will pay a total of no more than RMB 5 billion for initial payments and potential payments for ADC-based product development, registration, and commercialization milestones based on sales, and tiered royalties based on global net sales.
According to reports, HS-20117/pm1080 is an EGFR/cMet bispecific antibody with a 1+1 heterologous dimer structure. It inhibits tumor growth and survival by specifically targeting the tumor antigens EGFR and cMet, and is currently in phase I clinical research.
Established in 2018, Pumis is a clinical-stage biopharmaceutical company focusing on the development of innovative biopharmaceuticals in the field of malignant tumors and autoimmune diseases.